Delcath Systems, Inc.  

(Public, NASDAQ:DCTH)   Watch this stock  
Find more results for DCTH
2.46
Jul 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.38 - 10.56
Open     -
Vol / Avg. 0.00/62,280.00
Mkt cap 23.23M
P/E     -
Div/yield     -
EPS -2.97
Shares 9.44M
Beta 2.28
Inst. own 8%
Aug 4, 2014
Q2 2014 Delcath Systems, Inc. Earnings Release (Estimated) Add to calendar
Jun 10, 2014
Delcath Systems, Inc. 2014 Annual Shareholder Meeting
May 7, 2014
Q1 2014 Delcath Systems, Inc. Earnings Conference Call - Webcast
May 7, 2014
Q1 2014 Delcath Systems, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -1702.58% -3838.48%
Operating margin -1631.93% -4179.62%
EBITD margin - -4037.09%
Return on average assets -57.86% -89.75%
Return on average equity -70.86% -121.03%
Employees 37 -
CDP Score - -

Address

35TH FLOOR, 810 SEVENTH AVENUE
NEW YORK, NY 10019
United States - Map
+1-212-4892100 (Phone)
+1-212-4892102 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs. On April 13, 2011, it received Conformite Europeenne (CE) mark approval for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).

Officers and directors

Gabriel S. Leung Independent Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Graham G. Miao Ph.D. Interim Co-President and Co-Chief Executive Officer, Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Jennifer Simpson Ph.D. Interim Co-President and Co-Chief Executive Officer, Executive Vice President, Global Head - Business Operations
Age: 45
Bio & Compensation  - Reuters
Peter J. Graham Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources
Age: 46
Bio & Compensation  - Reuters
John Purpura Executive Vice President - Regulatory Affairs and Quality Assurance
Age: 50
Bio & Compensation  - Reuters
Barbra Keck Vice President, Controller
Age: 35
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 56
Bio & Compensation  - Reuters
Tasos G. Konidaris Independent Director
Age: 48
Bio & Compensation  - Reuters
Harold S. Koplewicz M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Laura A. Philips Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters